Market Risers: AstraZeneca, Compass Group, easyJet

Broker Ratings

The stock price for AstraZeneca with ticker code: LON:AZN has moved up 2.25% or 195 points during today’s session so far. Market buyers have remained optimistic throughout the session. The periods high figure was 8982 and hitting a low of 8825.94. The amount of shares exchanged has so far reached 1,224,569 with the daily average traded share volume around 2,273,368. A 52 week high for the stock is 8982 around 314 points different to the previous business close and a 52 week low sitting at 6736 which is a difference of 1932 points. AstraZeneca now has a 20 simple moving average of 8486.06 and now the 50 day SMA of 8471.68. The market capitalisation is now £137,609.38m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Friday, September 24, 2021 at 12:04:20 PM GMT with the stock price trading at 8863 GBX.

Shares of Compass Group ticker lookup code: LON:CPG has stepped up 1.5% or 22 points throughout today’s trading session so far. Investors seem confident during the session. Range high for the period so far is 1493.5 and hitting a low of 1455. The number of shares traded by this point in time totalled 298,478 with the average number of shares traded daily being 3,095,047. The 52 week high for the share price is 1657.03 some 188.53 points difference from the previous days close and putting the 52 week low at 1029 is a variance of 439.5 points. Compass Group now has a 20 SMA at 1492.3 and also a 50 day moving average of 1501.23. Market capitalisation for the company is £26,591.00m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Compass Group being recorded at Friday, September 24, 2021 at 11:52:31 AM GMT with the stock price trading at 1490.5 GBX.

Shares of easyJet EPIC code: LON:EZJ has increased 4.42% or 28.89 points in today’s trading session so far. Investors are a positive bunch throughout the session. Range high for the period has seen 683.41 meanwhile the session low reached 644.6. Volume total for shares traded at this point reached 1,641,146 with the average number of shares traded daily being 7,413,234. The stock 52 week high is 921.89 which is 268.09 points difference from the previous close and the 52 week low at 385.43 making a difference of 268.37 points. easyJet now has a 20 moving average of 662.48 and now the 50 day moving average now of 691.05. The current market cap is £5,172.24m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for easyJet being recorded at Friday, September 24, 2021 at 11:52:27 AM GMT with the stock price trading at 682.69 GBX.

Share on:

Latest Company News

AstraZeneca H1 2026 revenue rises 9% as growth momentum continues

AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease offset Farxiga and China headwinds. The company raised its interim dividend, secured 30 approvals, and reaffirmed full-year guidance and its $80 billion 2030 revenue goal.

Astrazeneca reports positive survival data for Sone-Ve in gastric cancer trial

Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial.

Astrazeneca secures EU approval for Etcamah in ER-positive breast cancer

Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer.

Compass Group reports continued strong quarterly revenue growth

Compass Group reported 7.1% organic revenue growth in the third quarter and said it remains on track for another year of strong earnings growth.

Astrazeneca secures global rights to Zegfrovy in EGFR-mutated lung cancer

Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio.

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy...

    Search